REPLIMUNE GROUP, INC. Proceeds from Common Stock Issued
REPLIMUNE GROUP, INC. (REPL) reported Proceeds from Common Stock Issued of $0 for the 6-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-11-06
- REPLIMUNE GROUP, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00.
- REPLIMUNE GROUP, INC. proceeds from issuance of common stock for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- REPLIMUNE GROUP, INC. proceeds from issuance of common stock for the quarter ending 2025-03-31 was -$1.00K.
- REPLIMUNE GROUP, INC. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $107.53M.
- REPLIMUNE GROUP, INC. proceeds from issuance of common stock for fiscal 2025 was $155.73M.
- REPLIMUNE GROUP, INC. proceeds from issuance of common stock for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- REPLIMUNE GROUP, INC. proceeds from issuance of common stock for fiscal 2023 was $149.85M.
- REPLIMUNE GROUP, INC. proceeds from issuance of common stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 1 month as first filed | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | -$1.00K derived: sum of 3 quarters · filed 2025-11-06 | $107.52M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | -$1.00K derived: sum of 2 quarters · filed 2025-08-07 | $107.52M derived: sum of 3 quarters · filed 2025-08-07 | $107.52M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2025-03-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | $107.52M derived: sum of 2 quarters · filed 2025-05-22 | $107.52M derived: sum of 3 quarters · filed 2025-11-06 | $155.73M 10-K · filed 2025-05-22 | |||
| 2024-12-31 | $107.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-12 | $107.53M derived: sum of 2 quarters · filed 2025-11-06 | $155.73M 10-Q · filed 2025-02-12 | $155.73M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06 | $48.20M 10-Q · filed 2025-11-06 | $48.20M derived: sum of 3 quarters · filed 2025-11-06 | $48.20M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $48.20M 10-Q · filed 2025-08-07 | $48.20M derived: sum of 2 quarters · filed 2025-08-07 | $48.20M derived: sum of 3 quarters · filed 2025-08-07 | $48.20M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | $0.00 derived: sum of 2 quarters · filed 2025-05-22 | $0.00 derived: sum of 3 quarters · filed 2025-05-22 | $0.00 10-K · filed 2025-05-22 | |||
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-12 | $0.00 derived: sum of 2 quarters · filed 2025-02-12 | $0.00 10-Q · filed 2025-02-12 | -$248.00K derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | -$248.00K derived: sum of 3 quarters · filed 2024-11-12 | $6.45M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | -$248.00K derived: sum of 2 quarters · filed 2024-08-08 | $6.45M derived: sum of 3 quarters · filed 2024-08-08 | $13.15M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | -$248.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16 | $6.45M derived: sum of 2 quarters · filed 2024-05-16 | $13.15M derived: sum of 3 quarters · filed 2024-05-16 | $149.85M 10-K · filed 2024-05-16 | |||
| 2022-12-31 | $242.60M 10-K · filed 2024-05-16 | $242.63M 10-Q · filed 2023-02-09 | $6.70M 10-Q · filed 2023-02-09 | $13.40M derived: sum of 2 quarters · filed 2023-11-07 | $150.10M 10-Q · filed 2024-02-08 | $44.44M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-09-30 | $6.70M 10-Q · filed 2023-11-07 | $6.70M 10-Q · filed 2023-11-07 | $37.44M 10-Q · filed 2022-11-03 | $37.74M derived: sum of 3 quarters · filed 2023-11-07 | $37.74M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $31.04M 10-Q · filed 2022-08-04 | $31.04M derived: sum of 2 quarters · filed 2023-05-18 | $31.04M derived: sum of 3 quarters · filed 2023-05-18 | $31.04M derived: sum of 4 quarters · filed 2023-05-18 | |||
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18 | $0.00 derived: sum of 2 quarters · filed 2023-05-18 | $0.00 derived: sum of 3 quarters · filed 2023-05-18 | $0.00 10-K · filed 2023-05-18 | |||
| 2021-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-09 | $0.00 derived: sum of 2 quarters · filed 2023-02-09 | $0.00 10-Q · filed 2023-02-09 | $0.00 derived: sum of 4 quarters · filed 2023-02-09 | |||
| 2021-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 3 quarters · filed 2022-11-03 | $211.22M derived: sum of 4 quarters · filed 2022-11-03 | |||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 2 quarters · filed 2022-08-04 | $211.22M derived: sum of 3 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19 | $211.22M derived: sum of 2 quarters · filed 2022-05-19 | $286.11M 10-K · filed 2022-05-19 | ||||
| 2020-12-31 | $211.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-03 | $286.11M 10-Q · filed 2022-02-03 | |||||
| 2020-10-31 | $270.00M 10-Q · filed 2023-08-03 | $269.98M 10-Q · filed 2021-02-04 | |||||
| 2020-09-30 | $74.88M 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | $107.80M 10-Q · filed 2023-08-03 | $107.78M 10-Q · filed 2020-08-07 | |||||
| 2019-12-31 | $85.60M 10-K · filed 2021-05-20 | ||||||
| 2019-11-30 | $85.60M 10-Q · filed 2023-08-03 | $85.60M 10-Q · filed 2021-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |